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patients out of total 835 patients reported. In pediatric cohort
165 patients suffered from malignancies, 356 patients were
transplanted for non-malignant diseases; 437 underwent a
ﬁrst SCT, 87 had a subsequent transplant. In adult group 626
were treated for hematological malignancies and 18 for non-
malignant diseases (SAA or thalassemia). No data on auto-
SCT in adults were published after 2004. The majority of
pediatric patients received treosulfan in dose 39-45 mg/m2
(332 patients, 62%). Most of adult patients treated after 2007
received dose of 42 mg/m2.
Results: The main indications for treosulfan use in pediatric
population were non-malignant diseases (68%) or second
SCT, while among adults older age (>50 years) and/or
comorbidities disqualifying from myeloablative condition-
ing. No correlation between the given treosulfan dose and
the grade III/IV toxicity was observed both in children and in
adults. No association between dose and GVHD, OS, DFS,
relapse incidence and TRMwas found both in children and in
adults.
Conclusions: Treosulfan-based conditioning with its low
toxicity proﬁle and dose-dependent myelotoxicity is a good
option in children treated with non-malignant diseases.
Additionally, both children and adults not eligible for con-
ventional transplant regimen can be offered this treatment
with acceptable results. Toxicity and survival were similar in
children and adults, while acute and chronic GVHD incidence
were higher in adult population.391
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Donor-derived malignancy (DDM) is a rare but often fatal
complication of alloBMT, with a reported incidence of 0.1-5%.
AlloBMT utilizing high-dose post-transplantation cyclo-
phosphamide (PT/Cy) as GVHD prophylaxis produces excel-
lent rates of engraftment and low rates of acute and chronic
GVHD. Because exposing the allograft to cytotoxic chemo-
therapy may theoretically increase the risk of DDM, we
evaluated the incidence of DDM after alloBMT with PT/Cy.
From 2000-2012, 790 patients (median age 51y, range 1-74y)
received T-cell replete alloBMT with high-dose PT/Cy at
Johns Hopkins, including 313 (40%) who received PT/Cy as
sole GVHD prophylaxis. Of these transplants, 349 (44%) were
HLA-haploidentical and 346 (44%) were myeloablative. Me-
dian donor age was 41y (range 13-79y). With a median
follow-up of 3y (range, 0.8-9.4y) in patients without events,
the 3 year PFS and OS probabilities were 42% and 56%
respectively. Five cases (5/790¼0.6%) of DDMwere identiﬁedas well as one case of clonal, donor-derived LGL leukemia
that resolved without any therapy. By competing-risk anal-
ysis, the probability of DDM was 0.6% at 1 y, 0.8% at 5 y, and
2% overall (Figure). In the 5 identiﬁed cases of DDM, the
median patient age was 41y (range 18-65 y) at BMT and
median donor age was 41y (31-67y). These patients were
initially transplanted for ALL (1), NHL (3), or Hodgkin lym-
phoma (1). Two patients received myeloablative condition-
ing and 3 received additional GVHD prophylaxis with
mycophenolate mofetil and tacrolimus. The median time
from BMT to the diagnosis of DDMwas 1.3y (range 0.5-6.3y).
DDMs consisted ofMDS (1), AML (3), and CMML (1). All of the
patients received treatment for their DDM; 2 are long term
survivors and 3 died of their DDM. The incidence of devel-
oping a DDM after high-dose PT/Cy is rare, and is within the
range reported for other transplant platforms.392
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Introduction: Allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT) is the only potentially curative treat-
ment option for MF. The role of ex evivo TCD allo-HSCT
hasn’t been reported in patients with advanced MF.
Patients: Between 5/1990-4/2013, 12 pts underwent TCD
transplant at MSKCC for MF; 9 had primary MF, 2 post ET and
1 post MDS. Median age was 56 (42.7-65.5). Disease status
prior to transplant per DIPSS was: intermediate-1 (4), inter-
mediate-2 (6), and high-risk (2). Splenectomy prior to
transplant was performed in 8 patients. JAK2 V617Fmutation
status was known on ﬁve patients and was detected on 3.
Five pts received a TCD marrow graft and were conditioned
with a TBI-based regimen and 7 pts received TCD peripheral
blood graft and were conditioned with a chemotherapy
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abine. All patients received ATG to prevent graft rejection.
Donors were matched related (8) andmatched unrelated (4).
BM grafts were depleted of T-cells using the soybean
agglutinin method followed by sheep RBC rosetting, and PB
grafts by immunomagnetic CD34+ selection (Isolex initially
and CliniMACS after 09/2011).
Results: Three pts died early and were not evaluable for
engraftment, the remaining 9 pts engrafted. None of these pts
developed acute or chronic GvHD after the primary graft. Of
the 9 pts evaluable for long term follow up, 8 are alive with a
median follow up time of 12.1 months (3.3-196months). One
pt relapsed 15 months post initial transplant and achieved
remission after DLI. This patient developed acute gut GVHD
that responded to steroids. Two additional pts received low
dose DLI (0.5x106CD3 cells/kg), one for recurrent viral in-
fections and the other as prophylaxis for relapse. These 2 pts
had no GvHD post-DLI. Out of the 4 pts who did not undergo
pre-transplant splenectomy, one required post transplant
splenectomy for severe persistent thrombocytopenia which
resolved post splenectomy. JAK2 mutation was not detected
post transplant in any of the 3 pts.
In this small series of pts, eight out of twelve, 66%, are
alive; two of the ﬁve pts in the subgroup cyto-reduced with
TBI based regimen and six of the seven patients in the sub-
group cyto-reduced with chemotherapy only regimen. The
causes of death were: toxicity of the preparative regimen
(TBI) in 2, intra-cranial hemorrhage in 1 and unknown in the
4 thpatient who died more than 2 years post transplant with
no evidence of disease.
Conclusions: TCD transplantation can offer long term cure
for patients with advanced chronic MF and with no evidence
of GvHD in this small cohort of patients. The early experience
at MSKCCwith TCD transplant was associatedwith high rates
of early mortality likely related to the high intensity condi-
tioning regimen containing TBI. The current regimen of
busulphan, melphalan, ﬂudarabine and ATG has been well
tolerated and the majority of pts are alive and disease free.393
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Aim: Multicenter phase II study has been conducted to
investigate whether myeloablative dose of intravenous
busulfan (ivBu) can be used for elderly recipients.
Method: This study started in September 2009, and 32
centers participated (Trial identiﬁer: UMIN000002426). Pa-
tients aged from 55 to 70with acutemyeloid leukemia (AML)
or myelodysplastic syndrome (MDS) who were planned for
allo-SCT (bone marrow (BM), peripheral blood (PB), and cord
blood (CB)) were enrolled. Pretransplant conditioining con-
sisted of 30 mg/m2 of ﬂudarabine (Flu) for 6 days (total 180
mg/m2) and 3.2 mg/kg of ivBu for 4 days (divided by 4 daily,
total 12.8 mg/kg) with or without total body irradiation
depending on type of donor cells. Calcineurine inhibitors +
methotrexate for BM or PB recipients, and tacrolimus +
mycophenolate mofetil were used for CB recipients.
Result: Thirty-eight patients were enrolled. Median age was
60 (55-68), 22 male and 16 female, 31 AML and 7 MDS were
included. Donors were 8 matched and 2 1-Ag/allele-mis-
matched related BM/PB, 8 matched and 4 1-Ag/allele-mis-
matched unrelated BM, and 16 CB (2-Ag-mismatched).
There was 1 whose total dose of ivBu was reduced (11.2 mg/
kg) due to neurotoxicity (grade III). Thirty-ﬁve achieved
neutrophil recovery (median day 17 (range, 11-45)). There
was 1 who died from NRM early before engraftment (CB
recipient, day 27) due to cerebral hemorrhage, and were 2
who failed to engraft (both CB recipients, one due to early
relapse, and the other due to rejection). There were 2 VOD/
SOS observed. Cumulative incidences of grade II-IV and III-IV
acute GVHD were 37% and 16%, respectively. With respect to
donor type, no grade III-IV acute GVHD was observed in
transplants from matched related donors. Cumulative
incidence of total chronic GVHD was 38%. Up to 24 months
post-transplant, there were 11 relapse, and 7 non-relapse
mortality. Cumulative incidences of non-relapse mortality
and relapse at 2-year post-transplant were 21% and 31%,
respectively. Overall and event-free survivals were estimated
to be 58 % and 53 % at 2 year post-transplant.
Conclusions: Myeloablative conditioning using Flu/ivBu12.8
mg/kg +/- TBI was well tolerated with acceptable low toxic-
ities and was sufﬁcient to allow donor cell-engraftment post
allo-SCT for elderly patients with AML or MDS. Given the
promising results of OS and PFS, phase II studies in much
larger scale are now under investigation.394
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Background: Inﬂuenza is one of the most common virus
causing respiratory tract infection in HM patients and HSCT
recipients. Severely immunocompromised pts suffer more
severe disease, prolonged viral shedding, emergence of
resistance as well as highermortality rate. Studies comparing
characteristics and outcomes of pandemic H1N1 and
